The effect of tumor laterality on prognosis in metastatic renal cell carcinoma

Year 2024, , 134 - 139, 30.08.2024

Özlem Doğan , Hayriye Şahinli , Yakup Duzkopru , Perihan Perkin , Esra Zeynelgil

https://doi.org/10.30569/adiyamansaglik.1446010

Abstract

Aim: In metastatic renal cell carcinoma (RCC), prognosis relies on various factors. Tumor lateralization's role is still debated. Our study examined how tumor localization affects survival in metastatic RCC patients.Materials and Methods: The study retrospectively analyzed 80 patients with metastatic renal cell carcinoma, diagnosed between January 1999 and December 2021.
Results: Eighty patients were evaluated. The median age at diagnosis was 60 (range 37-86). Tumors were in the right kidney for 39 patients (48.8%) and in the left kidney for 41 patients (51.2%). Of these patients, 58 (72.5%) had de novo metastatic disease, while 22 (27.5%) had recurrences during follow-up. Tumor localization showed no significant association with age (p=0.684), gender (p=0.761), ECOG performance status (p=0.326), primary tumor surgery (p=0.697), or lung metastasis (p=0.495). However, a significant association was found with liver metastasis (p=0.032). There was no significant difference in median survival between right and left-sided tumors (p=0.266).
Conclusion: In our study, survival showed no correlation with tumor lateralization in metastatic RCC.

Keywords

Renal cell carcinoma, Lateralization, Metastazis, Kidney

Ethical Statement

The study was conducted according to the principles of the Helsinki Declaration and was approved by the Ankara Etlik City Hospital Ethics Committee on April 5, 2023, with approval number 2023-043.

Supporting Institution

The authors received no financial support for the research and/or authorship of this article.

Thanks

None

Metastatik renal hücreli karsinomda tümör lateralitesinin prognoza etkisi

Abstract

Amaç: Metastatik renal hücreli kanserlerde (RCC) prognoz prognostik faktörlere bağlıdır. Tümör lateralizasyonun bu faktörlerden biri olup olmadığı halen tartışmalıdır. Çalışmamızda metastatik RCC ile takip edilen hastalarda tümörün yerleşiminin sağkalım üzerine etkisini araştırdık.
Gereç ve Yöntem: Çalışmada Ocak 1999 ve Aralık 2021 arasında metastatik renal hücreli kanser tanısı alan 80 hasta retrospektif olarak incelendi.
Bulgular: 80 hasta değerlendirildi. Median tanı yaşı 60 (37-86) idi. 39 (%48,8) hastada tümör sağ böbrekte, 41(%51,2) hastada sol böbrekte idi. Hastaların 58’i (%72,5) denova metastatik iken 22 (%27,5) hastada takipte nüks gelişmişti. Tümör lokalizasyonu ile yaş (p=0.684), cinsiyet (p=0.761), ECOG ps (p=0.326), tümör primerine cerrahi yapılması (p=0.697) ve akciğer metastazı (p=0.495) arasında anlamlı ilişki yokken, karaciğer metastazı arasında anlamlı ilişki saptandı (p=0.032). Sağ ve sol lokalizasyonlu tümör arasında median sağkalım açısından anlamlı fark yoktu (p=0.266).
Sonuç: Çalışmamızda, metastatik RCC'de sağkalım ile tümör lateralizasyonu arasınd ilişki bulunamadı.

Keywords

Renal hücreli karsinom, Lateralizasyon, Metastaz, Böbrek

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
• Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. American family physician. 2019;99(3):179-184.
• Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. European urology. 2011;60(4):615-621.
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2017;15(6):804-834.
• Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World journal of urology. 2018;36:1943-1952.
• Hizal M, Sendur MA, Yasar HA, et al. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Journal of Oncology Pharmacy Practice. 2020;26(7):1583-1589.
• Lucca I, de Martino M, Hofbauer SL, Zamani N, Shariat SF, Klatte T. Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. World journal of urology. 2015;33:2045-2052.
• Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet. 2016;387(10032):2008-2016.
• Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. The Journal of urology. 2005;174(2):466-472.
• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. New England Journal of Medicine. 2017;376(4):354-366.
• Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS medicine. 2013;10(2):e1001381.
• Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clinical Cancer Research. 2011;17(16):5443-5450.
• Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. European urology. 2011;60(4):644-661.
• Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. The American journal of surgical pathology. 2013;37(10):1490-1504.
• Patard J-J, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. Journal of Clinical Oncology. 2005;23(12):2763-2771.
• Mehmet U, Yildirim EÇ, Semiz HS, et al. Metastatik Renal Hücreli Kanser Hastalarında Genel Sağkalım Üzerine Etkili Faktörlerin İncelenmesi: Dokuz Eylül Üniversitesi Tıbbi Onkoloji Kliniği Örneği. Batı Karadeniz Tıp Dergisi. 2022;6(2):165-171.
• Guo S, Yao K, He X, et al. Prognostic significance of laterality in renal cell carcinoma: a population‐based study from the surveillance, epidemiology, and end results (SEER) database. Cancer medicine. 2019;8(12):5629-5637.
• Delahunt B, Bethwaite P, Nacey JN. Renal cell carcinoma in New Zealand: a national survival study. Urology. 1994;43(3):300-309.
• Kradjian RM, Bennington JL. Renal carcinoma recurrent 31 years after nephrectomy. Archives of Surgery. 1965;90(2):192-195.
• Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiology Biomarkers & Prevention. 1999;8(12):1117-1121.
• Molina DK, DiMaio VJ. Normal organ weights in men: part II—the brain, lungs, liver, spleen, and kidneys. The American journal of forensic medicine and pathology. 2012;33(4):368-372.
• Schünke M, Schulte E, Schumacher U. Hals und Innere Organe: 78 Tabellen. Thieme; 2005.
• Strauss A, Uhlig J, Lotz J, Trojan L, Uhlig A. Tumor laterality in renal cancer as a predictor of survival in large patient cohorts: a STROBE compliant study. Medicine. 2019;98(17):e15346.
• Nini A, Larcher A, Cianflone F, et al. The effect of anatomical location of lymph node metastases on cancer specific survival in patients with clear cell renal cell carcinoma. Frontiers in Surgery. 2018;5:26.
• Roychoudhuri R, Putcha V, Møller H. Cancer and laterality: a study of the five major paired organs (UK). Cancer causes & control. 2006;17:655-662.
• Russo P, Jang TL, Pettus JA, et al. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008;113(1):84-96.